Table of Contents
ISRN Immunology
Volume 2012, Article ID 926817, 11 pages
Research Article

Intratumoral TLR-4 Agonist Injection Is Critical for Modulation of Tumor Microenvironment and Tumor Rejection

1Faculdade de Biociências e Instituto de Pesquisas Biomédicas, Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Avenida Ipiranga 6690, 2° Andar, 90680-001 Porto Alegre, RS, Brazil
2Departments of Molecular Microbiology and Immunology, Veterans Affairs Medical Center, Oregon Health and Science University, Portland, OR 97239, USA

Received 9 May 2012; Accepted 20 June 2012

Academic Editors: K. Müller and A. Vicente

Copyright © 2012 Fabio Luiz Dal Moro Maito et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [4 citations]

The following is the list of published articles that have cited the current article.

  • Linda Hammerich, Adam Binder, and Joshua D. Brody, “In situ vaccination: cancer immunotherapy both personalized and off-the-shelf,” Molecular Oncology, 2015. View at Publisher · View at Google Scholar
  • Linda Hammerich, Nina Bhardwaj, Holbrook E Kohrt, and Joshua D Brody, “ In situ vaccination for the treatment of cancer ,” Immunotherapy, 2016. View at Publisher · View at Google Scholar
  • Monika Cervinkova, Petra Kucerova, and Jana Cizkova, “Spontaneous regression of malignant melanoma - is it based on the interplay between host immune system and melanoma antigens?,” Anti-Cancer Drugs, vol. 28, no. 8, pp. 819–830, 2017. View at Publisher · View at Google Scholar
  • Maryam A. Shetab Boushehri, and Alf Lamprecht, “TLR4-based immunotherapeutics in cancer: a review of the achievements and shortcomings,” Molecular Pharmaceutics, 2018. View at Publisher · View at Google Scholar